oral glp 1 analogues GLP-1 Medication Helps Patients Maintain Weight Loss | Research Peptidyl and Non-Peptidyl Oral Glucagon-Like

[DOI] [PMC free article] [PubMed] [Google Scholar] 191

Key Implementation Points Standard monotherapy escalates from 0.3 mg to 4.5 mg weekly over 20 weeks Combination therapy (CagriSema) reaches maintenance at cagrilintide 2.4 mg plus semaglutide 2.4 mg weekly Gradual escalation minimizes gastrointestinal side effects and allows metabolic adaptation Individual adjustment based on tolerance and response optimizes outcomes Proper administration technique and site rotation ensure consistent absorption Comprehensive monitoring tracks both efficacy markers and safety parameters Actionable Next Steps For fitness instructors and health coaches : Develop educational materials explaining peptide therapy basics to help clients make informed decisions about emerging metabolic health approaches

SURPASS-CVOT is unique, in that it compares the dual incretin agonist with a GLP-1 RA that has been shown to have cardiovascular benefit in people with type 2 diabetes and high risk ASCVD

Yusri, K., Kumar, S., Fong, S., Gruber, J